IceCure Medical Ltd. (NASDAQ:ICCM) Receives Average Recommendation of “Hold” from Analysts

IceCure Medical Ltd. (NASDAQ:ICCM) has been assigned an average recommendation of “Hold” from the five analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $62.70.

A number of brokerages recently issued reports on ICCM. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a report on Tuesday, April 21st. Maxim Group lowered their price target on IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Finally, Alliance Global Partners began coverage on IceCure Medical in a report on Monday, May 4th. They issued a “buy” rating for the company.

IceCure Medical Stock Performance

ICCM stock opened at $5.93 on Tuesday. The company’s 50 day moving average price is $6.94 and its 200 day moving average price is $14.11. IceCure Medical has a fifty-two week low of $2.12 and a fifty-two week high of $42.00. The firm has a market capitalization of $16.66 million, a price-to-earnings ratio of -0.82 and a beta of 0.40.

IceCure Medical (NASDAQ:ICCM) last released its earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%.The firm had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $1.34 million. Equities analysts forecast that IceCure Medical will post -4.5 EPS for the current fiscal year.

Hedge Funds Weigh In On IceCure Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in IceCure Medical in the fourth quarter valued at approximately $39,000. Jane Street Group LLC acquired a new position in IceCure Medical in the fourth quarter valued at approximately $67,000. Finally, Concurrent Investment Advisors LLC acquired a new position in IceCure Medical in the fourth quarter valued at approximately $48,000. 0.62% of the stock is owned by institutional investors and hedge funds.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.